Dr. Rami Batniji describes how Evsse’s production process for cold technology can offer clinical benefits compared to traditional hyaluronic acid fillers.
While a new incectable market for the American aesthetics, plastic emergingers look into more closely on the way IT formulation can differ from determining options. Evolysse is a hyaluronic acid filler developed with cold technology -an approach that is designed to reduce the BDDE content and more closer natural replication ha -kins. Early clinical data suggest potential benefits in terms of effective, swelling and immune response.
To find out more about how this product fits treatment plans, Plastic surgery practice Speaked with Persanas in -NetWork doctor Rami Batniji, MD. Board-certified facial plastic in Newport Beach, Calif, Batniji shares its insights into the clinical performance of Evolysse and how it relates to other HA fillers that are in use today.
Plastic surgery practice: What should plastic arembuids know about Evsse when it comes in the American injection market, and how does it relate to existing hyaluronic acid fillers?
Rami Batniji, MD: Evolysse is a first of nice injection hyaluronic acid gel developed with cold technology. Because of this unique production process there are fewer quantities of BDDE (1.4 Butnedoil Ether), which is important because there can be immuno stimulant with regard to BDDE in fillers and results in reactions such as delayed onnset lumps in certain patients. Furthermore, cold technology may ensure a longer chain hyaluronic acid gel in Evolysse and the longer chains that occur more often in nature and therefore more comparable to natural hyaluronic acid.
PSP: What does it stand out from a clinical perspective about the formulation or performance of Evolysse in the treatment of moderate to severe wrinkles such as nasolabial folds?
Batniji: Evolysse has very low hydrophilic characteristics, which means that less swelling is caused with this hyaluronic acid comar to others. As such, injections must be carried out on full correction and “what you see is what you get” when completing the procedure. It is also efficient; Studies showed that this product offers a better correction with Leser quantities of product injection.
PSP: Are there specific demography of the patient or aesthetic goals that make Subrong a strong candidate for Evolysse about HA fillers?
Batniji: All patients who are candidates for hyaluronic acid injections would be suitable candidates for Evolysse.
PSP: What do your experience with the satisfaction of the patient and the lifetime of the results so far?
Batniji: According to the study carried out that was integrated in reaching the FDA approval for Evolysse, the satisfaction of the patient was very high and the duration was comparable to other hyaluronic acid fillers currently available on the American market.
PSP: How do you see Evsse adjustment in or reforming the current treatment plans, in particular in combination with other injectable or surgical procedures?
Batniji: In this current environment there is less more with hyaluronic acid fillers. Providers and patients want natural results with less product. Evolysse has been shown to be efficient, which means that reses can be achieved with less product. It has also been shown that it is more natural; It consists of hyaluronic acid with a longer chain that is comparable to what we see in nature. And it has Les BDDE, which can lead to less immune -mediated problems such as seen with other hyaluronic acid fillers. The production process for cold technology ensures supplications of unique characteristics of Evolysse. PSP
Lead photo: Evolysee
